knowledge -WSS

knowledge

author：comprehensive 2025-09-30 16:25:52 - browse：84744

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Websites selling Wegovy, Zepbound ingredients targeted by FDA

WSS

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

Resistance to opioid

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

focus

knowledge

leisure time

Medical leaders decry Supreme Court decision on affirmative action

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

At least 13 dead in Texas as scorching temps continue

AMAs digital advisors table RPM coding reform proposal, again

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Resistance to opioid

DIEP, the 'gold standard' of breast reconstruction, is under threat

Doctors on social media are being harassed and cyberbullied

Medical leaders decry Supreme Court decision on affirmative action

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Wikipedia

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Tome Biosciences co

Too many hospitalized Covid

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Congress must protect the remaining independent doctors

focus

focus

knowledge

focus